A Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy
Journal of Cachexia, Sarcopenia and Muscle · 2026-12 · 17 (6)
DOI: 10.1002/jcsm.70420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 11.11.2026. Verfasst von Tomas Baka und 15 weiteren Autor:innen. Beteiligte Einrichtung: Myocardial Biology Unit, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Muscle, Skeletal, Cardiomyopathy, Hypertrophic, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Hypertrophic cardiomyopathy (HCM) involves left ventricular hypertrophy and metabolic dysfunction. Given the role of skeletal muscle in systemic metabolism, we investigated whether activin type II receptor inhibition with CDD866, a murinized bimagrumab analogue that induces skeletal muscle hypertrophy, improves physical performance and cardiometabolic remodelling in established HCM.
Methods
Twenty‐four‐week‐old male mice harbouring the cardiac myosin R403Q mutation received CDD866 or isotype antibody (20 mg/kg subcutaneously every 3 days) for 4 weeks; wild‐type (WT) littermates received isotype antibody. Assessments included body composition, muscle imaging and histology, grip strength, treadmill exercise, glucose tolerance, echocardiography, cardiac histopathology, myocardial substrate oxidation by 13 C nuclear magnetic resonance in isolated beating hearts and cardiac transcriptomics and proteomics. Values are mean ± SEM.
Results
Compared with R403Q placebo, CDD866 increased lean mass (22.5 ± 0.6 vs. 18.7 ± 0.5 g; p < 0.001), grip strength (135.3 ± 3.4 vs. 99.9 ± 4.3 cN; p < 0.0001) and treadmill distance (99.8 ± 1.7 vs. 77.2 ± 3.2 m; p < 0.0001). Hindlimb muscle volume increased by 24 ± 8% ( p < 0.05), and individual muscle weights increased by 44%–87% (all p < 0.0001). CDD866 reduced total left ventricular wall thickness (1.80 ± 0.03 vs. 1.98 ± 0.03 mm; p < 0.001) and improved E/A ratio (1.31 ± 0.04 vs. 0.99 ± 0.04; p < 0.001) and early diastolic mitral annular velocity (18.6 ± 0.7 vs. 14.0 ± 0.7 mm/s; p < 0.01). Cardiomyocyte cross‐sectional area and myocardial fibrosis decreased by 32 ± 6% ( p < 0.0001) and 69 ± 31% ( p < 0.01), respectively. Glucose tolerance was impaired in R403Q mice versus WT ( p < 0.01), with a nonsignificant reduction in AUC following CDD866 ( p = 0.223). CDD866 increased the fractional contribution of fatty acids to myocardial oxidative metabolism (0.66 ± 0.02 vs. 0.38 ± 0.05; p < 0.01) and reduced 13 C‐lactate output (15.3 ± 2.5 vs. 40.2 ± 3.8 nmol/min; p < 0.001). Consistent with these measurements, cardiac RNA‐seq GSEA showed HCM‐associated suppression and CDD866‐associated enrichment of fatty acid oxidation, pyruvate metabolism, the tricarboxylic acid cycle, oxidative phosphorylation, ATP synthesis and branched‐chain amino acid catabolism (all FDR q < 0.05). Integrated transcriptomic and proteomic upstream regulator predictions provided an exploratory regulatory context for these metabolic findings.
Conclusions
CDD866 increased skeletal muscle mass and performance alongside improvements in cardiac remodelling, diastolic function and myocardial metabolism in established experimental HCM. Activin receptor inhibition offers a promising therapeutic avenue for HCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Myocardial Biology Unit, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
- Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
- Clinical and Translational Science Institute, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
- Vascular Biology Section, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
- Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Division of Interdisciplinary Medicine and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
ORCID-Profile: Tomas Baka, Sophia M Mirrione, Adam C Gower, Connor Haney, Simon T Dillon, Towia A Libermann, Kylie Heitman, Joseph T Brozinick, Flora Sam, Ivan Luptak
Förderung
- NCATS NIH HHS
- NHLBI NIH HHS
- NIH HHS
- National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH)
- National Institutes of Health (NIH) Clinical Translational Science Award
- National Institutes of Health (NIH) Shared Instrumentation Grants (SIG)
- American Heart Association (AHA)
- National Institutes of Health
Zitieren
APA
Baka, T., Mirrione, S. M., Qin, F., Gower, A. C., He, H., Haney, C., Su, K. M., Dillon, S. T., Libermann, T. A., Heitman, K., Ryan, A. P., Brozinick, J. T., Seta, F., Pimentel, D. R., Sam, F., & Luptak, I. (2026). A Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy. Journal of Cachexia, Sarcopenia and Muscle, 17(6). https://doi.org/10.1002/jcsm.70420
Vancouver
Baka T, Mirrione SM, Qin F, Gower AC, He H, Haney C, et al. A Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(6). doi:10.1002/jcsm.70420
BibTeX
@article{Baka2026,
author = {Baka, Tomas and Mirrione, Sophia M and Qin, Fuzhong and Gower, Adam C and He, Huamei and Haney, Connor and Su, Kuan Ming and Dillon, Simon T and Libermann, Towia A and Heitman, Kylie and Ryan, Andrew P and Brozinick, Joseph T and Seta, Francesca and Pimentel, David R and Sam, Flora and Luptak, Ivan},
title = {A Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
volume = {17},
number = {6},
doi = {10.1002/jcsm.70420}
}
EUVIMED